Pagoclone going the Zoloft way?
Executive SummaryPfizer nearly rejected Zoloft clinical development twice before going on to market the drug, Indevus tells conference call on Pfizer's termination of pagoclone contract. "Twice in the history of Zoloft, in the early days at Pfizer, the compound was facing cancellation over dose and efficacy issues and obviously Zoloft came through to be one of the most successful antidepressants today," the company said...
You may also be interested in...
Submission surge in late 2019 means a spike in late summer 2020 user fee goals, including 16 novel agents in August alone.
Keeping Track: Approvals For Tazverik And Tepezza, Priority Reviews For Belantamab Mafodotin And Lynparza
The latest drug development news and highlights from our US FDA Performance Tracker.
Accelerated approval in epithelial sarcoma may de-risk the firm’s goals for approval of Tazverik in follicular lymphoma and other larger indications.